ESETEC® is the trade name of an expression and secretion system developed and patented by WACKER. It is based on an E. coli K12 strain and a series of highly expressive plasmids.
The E. coli secretion strain can transfer proteins in native conformation across the outer cell membrane into the culture medium. By combining plasmids and the special production strain, the subsequent production and purification processes can be streamlined and simplified from the earliest phases of development. As a result, therapeutic proteins are manufactured efficiently and cost-effectively.
The E. coli secretion strain is extremely stable during fermentation and is routinely employed in commercial-scale production using fermenters with capacities of up to 4 m³. Product yields can already exceed 10 g/l. The ESETEC® E. coli secretion technology is ideal for antibody fragment production.
WACKER’s ESETEC® secretion technology can increase product yields by up to 50%.